<DOC>
	<DOCNO>NCT01232894</DOCNO>
	<brief_summary>In 12-week study , patient randomize either open-label indacaterol standard care Chronic Obstructive Pulmonary Disease ( COPD ) treatment ; efficacy safety assess .</brief_summary>
	<brief_title>12-week Open-label Evaluation Efficacy Safety Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) ( moderatetosevere classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines , 2007 ) : Postbronchodilator force expiratory volume 1 second ( FEV1 ) &lt; 80 % ≥30 % predict normal value Postbronchodilator FEV1/FVC ( Forced Vital Capacity ) &lt; 70 % Current COPD bronchodilator treatment include LABA bronchodilator fix dose combination LABA Inhaled Corticosteroid ( ICS ) Patients history asthma Patients currently treat COPD tiotropium ( Spiriva® ) Patients diabetes Type I uncontrolled diabetes Type II Patients history certain cardiovascular comorbid condition Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>indacaterol</keyword>
	<keyword>COPD</keyword>
	<keyword>Long-acting beta2-agonist ( LABA )</keyword>
</DOC>